tirzepatide mastery course
Unit 3 of 12

The GIP Pathway

how tirzepatide activates the gastric inhibitory polypeptide receptor to improve metabolic function

The Forgotten Incretin

For years, GLP-1 dominated the incretin drug landscape while GIP was largely ignored -- or even considered counterproductive for weight loss. Tirzepatide's success rewrote that assumption. Built on a native GIP backbone, tirzepatide activates the GIP receptor with roughly 5x the potency of endogenous GIP, driving effects in beta cells, adipose tissue, and the central nervous system that complement its GLP-1 activity. This unit traces the GIP signaling cascade from receptor binding to metabolic outcomes.

GIP Signaling Cascade

Explore how tirzepatide activates the GIP receptor and the downstream effects in target tissues.

interactive GIP signaling cascade
60-70%
of the total incretin effect attributed to GIP in healthy individuals
42
amino acids in the native GIP hormone, secreted by k-cells in the duodenum
50-70%
of total insulin response to a meal accounted for by the incretin effect
20+ yrs
GIP was dismissed as a drug target due to GIP resistance in type 2 diabetes
central GIP effects are still being characterized. While animal studies demonstrate that GIP agonism can reduce food intake and potentiate GLP-1's anorectic effect, the exact contribution of central GIPR activity to tirzepatide's overall weight loss in humans has not been definitively quantified. The relative importance of central vs peripheral GIP effects remains actively debated.

key terms for this unit

G GIP incretin hormone
Glucose-dependent insulinotropic polypeptide, a 42-amino-acid incretin hormone secreted by k-cells in the duodenum and proximal jejunum. Historically the "forgotten incretin" despite being the dominant incretin in healthy individuals.
K k-cells cell type
Enteroendocrine cells in the duodenum and proximal jejunum that secrete GIP in response to dietary fats and carbohydrates within minutes of eating.
L lipid buffering adipose function
The ability of fat cells to efficiently uptake and store circulating triglycerides after meals. GIP receptor activation enhances lipid buffering, preventing harmful ectopic fat deposition in the liver, muscle, and pancreas.
E ectopic fat pathology
Fat deposited in organs where it does not normally accumulate, such as the liver, muscle, and pancreas. Ectopic fat drives insulin resistance, inflammation, and metabolic dysfunction.
I incretin effect physiology
The enhanced insulin secretion after oral nutrient intake beyond what intravenous glucose alone would trigger. Accounts for approximately 50-70% of the total insulin response to a meal.

the GIP pathway -- the simple version

what the "forgotten incretin" actually does and why it matters.

When you eat, cells in your upper intestine release a hormone called GIP (glucose-dependent insulinotropic polypeptide). GIP travels to the pancreas and tells insulin-producing cells to release more insulin -- but only when blood sugar is already high, which prevents dangerous lows. for decades, drug makers ignored GIP because diabetic patients seemed resistant to it. tirzepatide changed everything by delivering GIP at pharmacological doses far higher than the body produces naturally, overwhelming that resistance. beyond the pancreas, GIP also talks directly to fat cells, helping them absorb circulating fats efficiently so that lipids do not end up in the liver or muscles where they cause damage. emerging research even shows GIP receptors in the brain, where they may amplify the appetite-suppressing effects of GLP-1.

A advanced: the incretin effect term
The incretin effect refers to the enhanced insulin secretion that occurs after eating a meal compared to receiving the same amount of glucose intravenously. this amplification accounts for approximately 50-70% of the total insulin response to a meal. in healthy individuals, GIP is the dominant incretin, responsible for roughly 60-70% of this effect, with GLP-1 contributing the remaining 30-40%. GIP is secreted by K-cells in the duodenum within minutes of nutrient ingestion, particularly in response to dietary fats and carbohydrates.
advanced: GIP resistance and its reversal
In type 2 diabetes, the beta-cell response to GIP is markedly blunted -- a phenomenon called GIP resistance. This led researchers to dismiss GIP as a drug target for over 20 years. Tirzepatide's success overturned this assumption by delivering GIP agonism at concentrations far exceeding what native K-cells produce, effectively overcoming receptor desensitization. The mechanism likely involves sustained high-level receptor engagement that restores downstream cAMP/PKA signaling even in cells with reduced GIP receptor surface expression.
advanced: adipocyte lipid buffering
GIP receptors are abundantly expressed on adipocytes, unlike GLP-1 receptors which are sparse in fat tissue. When activated, GIP enhances lipid buffering -- the ability of fat cells to efficiently uptake and store circulating triglycerides after meals. This prevents ectopic fat deposition in the liver, muscle, and pancreas. GIP also improves adipose tissue blood flow and increases adiponectin secretion. During the caloric deficit created by tirzepatide's GLP-1 component, GIP shifts from promoting fat storage to supporting healthy adipose remodeling and preferential visceral fat mobilization.